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Abstract
Asymptomatic primary hyperparathyroidism (PHPT), a condition defined as hyperparathyroidism that
lacks specific symptoms or signs and with calcium levels of less than 1 mg/dL above the upper limit of
normal, is a common clinical problem. Two previous conferences on the management of
asymptomatic PHPT (a Consensus Development Conference and a National Institutes of Health
workshop) indicated that medical monitoring rather than surgery is appropriate in certain patients
with this condition. The Third International Workshop on the management of PHPT reviewed
evidence that has become available since the last workshop in 2002. The purpose of this report is to
describe recent advances reviewed during the third workshop on asymptomatic PHPT held in 2008.
Introduction and context
Primary hyperparathyroidism (PHPT) is increasingly
being diagnosed as a result of the detection of hypercal-
cemia by widespread use of multiphasic screening. The
increased diagnosis of hyperparathyroidism by screening
tests has disclosed a population of patients who have
subtle or absent symptoms and mild hypercalcemia
(<1 mg/dL above normal), which indicate asymptomatic
PHPT [1]. The asymptomatic aspect of PHPT has raised
new questions about the natural history and the manage-
ment of this disorder.
To develop guidelines for the management of asympto-
matic PHPT, a Consensus Development Conference and
a workshop were held at the National Institutes of Health
in October 1990 and in April 2002, respectively [2,3].
The summary statements generated by the two work-
shops represented a distillation of thoughts of partici-
p a n t sc o n v e n e dt od i s c u s sh o wt oc h a n g et h e
recommendations for physicians who care for patients
with asymptomatic PHPT. The panel of experts in the
two conferences considered questions specifically con-
cerning asymptomatic PHPT in the US; the applicability
of the guidelines regarding asymptomatic PHPT to
patients in other countries is not known. The two prior
reports found that medical monitoring rather than
surgery is appropriate in asymptomatic PHPT. However,
as surgery is considered to be the definitive therapy even
in asymptomatic patients, a decision to elect medical
monitoring should follow guidelines regarding the
severity of the manifestations of the disease and how
patients should be appropriately monitored.
A third workshop was prompted by a number of issues
that have arisen over the 6 years that followed the second
workshop. To address these issues, in May 2008, a panel
of international experts reviewed the evidence presented
by authorities in the field in order to respond to a total of
22 prespecified questions assigned to four categories: (a)
diagnosis of PHPT [4], (b) presentation of PHPT [5], (c)
surgery for PHPT [6], and (d) medical management of
PHPT [7].
Recent advances
The major differences in the management of asympto-
matic PHPT between the last workshop and the previous
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statement from the Third International Workshop
(please refer to [8] for the guidelines). Growing evidence
for reversible aspects of PHPT (such as improvement in
bone density, reduction in fractures, reduced frequency
of kidney stones, and improvements in some neurocog-
nitive elements) supports the greater use of parathy-
roidectomy by surgeons who are highly experienced in
this operation. The present guidelines suggest that
asymptomatic patients (no kidney stones, nephrocalci-
nosis, fractures, or other symptoms) should undergo
surgery if they are under the age of 50, if their serum
calcium is >1 mg/dL above normal, if their creatinine
clearance is <60 mL/minute, or if they have a bone
mineral density T-score of less than -2.5 at lumbar spine,
hip, or forearm (the Z-score is used in men under
50 years of age and in premenopausal women).
Hypercalciuria by itself is not considered an indication
for surgery. The consensus remains that asymptomatic
patients who do not meet surgical guidelines can be
managed safely without surgery by the monitoring of
biannual serum calcium levels, annual serum creatinine
levels, and bone mineral density every 1-2 years at three
sites. Pharmacological interventions have not been
adequately evaluated and require further study. The
workshop also identified the items to be placed on the
research agenda for asymptomatic PHPT over the next
decade [8].
Implications for clinical practice
Besides the guidelines for surgery and medical manage-
ment outlined above, the main messages for the clinical
management of asymptomatic PHPT, generated from
active discussion during the Third International Work-
shop, can be summarized as follows: First, vitamin
deficiency should be assessed in all patients suspected of
having PHPT, and vitamin D deficiency should be
cautiously corrected at the time it is detected. Second,
advances in the field clearly indicate testing for the
genetic forms of PHPT, especially in young subjects.
Third, the presence of a fragility fracture provides clinical
confirmation of osteoporosis and represents an
indication for surgical intervention independently of
bone mass measurement. There is also growing support
for the increased use of parathyroidectomy for asympto-
matic PHPT, especially when performed by high-volume
surgeons. Finally, cinacalcet, a drug that acts as a
calcimimetic, can be very effective in normalizing serum
calcium in PHPT, although it is approved in these settings
in only some countries and long-term studies still need to
be performed.
Abbreviation
PHPT, primary hyperparathyroidism.
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